Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) from a hold rating to a buy rating in a research note published on Wednesday morning. Separately, Needham & Company LLC dropped their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on […]

Leave a Reply

Your email address will not be published.

Previous post What is Seaport Res Ptn’s Forecast for LYV FY2024 Earnings?
Next post Zacks Research Predicts Increased Earnings for Raymond James